10-Q: Myomo Inc. Reports First Quarter 2024 Results, Focuses on Medicare Expansion

Myomo Inc. reports a net loss for Q1 2024, but highlights progress in Medicare reimbursement and plans for growth.

Summary

• Myomo Inc. reported a net loss of $3.8 million for the first quarter of 2024, compared to a $2.6 million loss in the same period last year.
• The company's revenue increased by 9% to $3.75 million, driven by higher product sales volume, although average selling prices were lower.
• Gross margin decreased to 61.2% from 67.0% due to lower average selling prices and increased manufacturing overhead.
• Operating expenses increased by 24% to $6.19 million, with significant increases in research and development, selling, clinical, and marketing, and general and administrative costs.
• The company's cash and cash equivalents totaled $5.4 million, with short-term investments of $5.5 million as of March 31, 2024.
• Myomo believes it can achieve cash flow breakeven on a quarterly basis by the fourth quarter of 2024, contingent on hiring 50 to 60 additional employees and maintaining supply chain stability.
• The company completed a registered direct equity offering in January 2024, generating net proceeds of approximately $5.4 million.
• Myomo is focusing on expanding its clinical, reimbursement, and manufacturing capacity to serve a higher volume of Medicare Part B patients.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there is positive progress in Medicare reimbursement and revenue growth, the increased net loss and reliance on a single insurer are concerning. The company's ability to achieve cash flow breakeven is contingent on several factors, adding uncertainty.

Positives

• Product revenue increased by 9% year-over-year, indicating growing demand for MyoPro products.
• The company successfully raised $5.4 million through a registered direct equity offering, strengthening its financial position.
• CMS has finalized payment determinations for MyoPro products, providing a clear path for Medicare reimbursement.
• Myomo is actively expanding its capacity to serve a higher volume of Medicare Part B patients, which is expected to drive future revenue growth.
• The company believes it can achieve cash flow breakeven by the fourth quarter of 2024.

Negatives

• The company reported a net loss of $3.8 million for Q1 2024, an increase from the $2.6 million loss in Q1 2023.
• Gross margin decreased to 61.2% due to lower average selling prices and increased manufacturing overhead.
• Operating expenses increased significantly, driven by higher R&D, sales, and administrative costs.
• The company's historical losses and cash used in operations raise concerns about its ability to continue as a going concern.
• Myomo is still reliant on a single insurer for a significant portion of its revenue, which poses a risk if that insurer changes its reimbursement policies.

Risks

• The company has a history of operating losses and may not achieve cash flow breakeven as planned.
• A significant portion of revenue is concentrated with a single insurer, and adverse changes in their reimbursement policy could negatively impact the business.
• Myomo relies on a single third-party manufacturer for key subassemblies, and any disruption could affect production.
• The market for myoelectric braces is new, and the rate of adoption is uncertain.
• Defects in products or software could adversely affect operations.
• The company is subject to extensive governmental regulations, and failure to comply could lead to product recalls.
• Cyber-attacks or security breaches could disrupt operations.
• The company's success depends on its ability to protect its intellectual property.
• The market price of the company's common stock may continue to be volatile.
• The company is subject to foreign currency fluctuations.

Future Outlook

Myomo believes it can achieve cash flow breakeven on a quarterly basis by the fourth quarter of 2024, contingent on hiring 50 to 60 additional employees and maintaining supply chain stability. The company plans to increase its clinical, reimbursement, and manufacturing capacity to serve a higher volume of Medicare Part B patients.

Management Comments

• Management's operating plans are primarily focused on increasing its clinical, reimbursement and manufacturing capacity in order to serve a higher volume of Medicare Part B patients in 2024.
• The Company believes that based on the final fees published by the Centers for Medicare and Medicaid Services (CMS) for the Companys products, which became effective on April 1, 2024, if the Company is able to hire at least 50 to 60 additional employees during the first half of 2024 as planned to increase its clinical, reimbursement and manufacturing capacity, and its supply chain is able to meet its volume requirements without disruption, the Company believes it can achieve cash flow breakeven on a quarterly basis by the fourth quarter of 2024.

Industry Context

The announcement comes as the medical device industry is seeing increased focus on wearable robotics and assistive technologies. Myomo's focus on Medicare reimbursement aligns with broader trends in healthcare towards value-based care and improved patient outcomes. The company's ability to scale production and expand its reach will be critical in a competitive market.

Comparison to Industry Standards

• Myomo's revenue growth of 9% is moderate compared to some high-growth medical device companies, but it is a positive sign given the company's focus on a niche market.
• The decrease in gross margin to 61.2% is a concern, as many medical device companies aim for higher margins to support R&D and sales efforts. Companies like Inogen (INGN) and ResMed (RMD) typically have gross margins above 70%.
• The increase in operating expenses, particularly in R&D, is typical for companies in the growth phase, but Myomo needs to ensure these investments translate into revenue growth.
• Myomo's cash position of $11 million is relatively low compared to larger medical device companies, highlighting the need for continued capital raises or improved cash flow.
• The company's focus on Medicare reimbursement is a strategic move, as it provides a stable revenue stream, but it also exposes the company to regulatory risks and changes in government policies. Companies like Stryker (SYK) and Medtronic (MDT) have diversified revenue streams, which reduces their reliance on a single payer.

Legal Proceedings

• During the fourth quarter of 2023, the Company settled an age discrimination claim by a former employee.
• The settlement was paid and all insurance proceeds were received during the three months ended March 31, 2024.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and the company's reliance on a single insurer.
• Employees may be impacted by the company's plans to hire additional staff and expand its operations.
• Customers (patients) may benefit from increased access to MyoPro products through Medicare reimbursement.
• Suppliers may see increased demand for components as the company scales production.
• Creditors may be concerned about the company's ongoing losses and its ability to achieve cash flow breakeven.

Next Steps

• The company plans to hire 50 to 60 additional employees during the first half of 2024 to increase its clinical, reimbursement, and manufacturing capacity.
• Myomo will focus on serving a higher volume of Medicare Part B patients.
• The company will continue to monitor its supply chain to ensure it can meet volume requirements without disruption.

Key Dates

Keywords

MyoPro, myoelectric orthotics, Medicare, reimbursement, medical devices, healthcare, robotic, orthotics, insurance, CMS